We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » Merck Drops Late-Stage Trial of Keytruda and Lynparza for Advanced Prostate Cancer
Merck Drops Late-Stage Trial of Keytruda and Lynparza for Advanced Prostate Cancer
Merck is stopping a phase 3 trial of its mega blockbuster anti-PD-1 therapy Keytruda (pembrolizumab) in combination with AstraZeneca’s blockbuster PARP inhibitor Lynparza (olaparib) for prostate cancer after an independent data monitoring committee recommended it do so.